Table 3. SARS-CoV-2 seroprevalence by different assays at selected periods corresponding to phases of community household surveys (HHS).
| SARS CoV-2 SEROPOSITIVE AT DELIVERY, % (95% CI) | |||||
|---|---|---|---|---|---|
| PHASE 1 | PHASE 2 | PHASE 3 | PHASE 4 | PHASE 5 | |
| May 4th- 12th | June 15th- 24th | July 20th- 29th | October 1st- 10th | January 14th- | |
| 2020 | 2020 | 2020 | 2020 | 23rd 2021 | |
| Household surveys (HHS) a | |||||
| Tests used | Maglumi | Maglumi | Roche+Maglumi | Roche+Maglumi | Roche+Maglumi |
| All | 4.7 | 11.4 | 17.9 | 26.2 | 29.9 |
| (2.7–7.0) | (9.2–13.6) | (15.0–20.9) | (22.5–29.9) | (26.2–33.5) | |
| (N = 517) | (N = 1183) | (N = 1470) | (N = 1129) | (N = 1194) | |
| Wealthiest (Half) | NA | 6.5 | 9.4 | 21.6 | 22.8 |
| (4.4–8.5) | (6.0–12.8) | (17–26.3) | (18.1–27.6) | ||
| Poorest (Half) | 16.0 | 22.0 | 30.4 | 36.4 | |
| (12.2–19.8) | (17.2–26.7) | (24.7–36.0) | (31.1–41.8) | ||
| Women only | NA | 11.2 | 18.4 | 25.7 | 30.7 |
| (8.5–13.9) | (15.2–22.1) | (21.7–29.6) | (27.1–34.4) | ||
| (N = 632) | (N = 785) | (N = 603) | (N = 638) | ||
| Women at delivery b | |||||
| Wondfo | NA | 54.7 | 24.7 | 15.9 | 12.5 |
| (30.9–78.5) | (16.7–32.7) | (11.6–20.2) | (4.2–20.8) | ||
| Roche | NA | 44.1 | 32.7 | 27.5 | 28.0 |
| (21.8–66.4) | (24.1–41.4) | (22.3–32.7) | (16.4–39.5) | ||
a Project soroEpi MSP: https://monitoramentocovid19.org
b The percentages seropositive are from the spline fit through the whole data, rather than time- specific numerators and denominators.